X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.fiercepharma.com/marketing/pfizers-velsipity-poised-outpace-bms-zeposia-ulcerative-colitis-market-must-head-further
https://www.prnewswire.com/news-releases/everest-medicines-announces-acceptance-of-velsipity-new-drug-application-in-macau-302084833.html
https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-velsipityr-patients#:~:text=(NYSE%3A%20PFE)%20announced%20today,lost%20response%2C%20or%20were%20intolerant
https://www.ema.europa.eu/en/documents/overview/velsipity-epar-medicine-overview_en.pdf-0
https://www.prnewswire.com/news-releases/everest-medicines-licensing-partner-pfizer-announces-us-fda-approves-etrasimod-for-adults-with-moderately-to-severely-active-ulcerative-colitis-301956907.html
https://www.prnewswire.com/news-releases/everest-medicines-announces-completion-of-patient-enrollment-in-phase-3-clinical-trial-of-etrasimod-in-asia-301826669.html
https://endpts.com/fda-and-ema-accept-pfizers-regulatory-submissions-for-ulcerative-colitis-drug/
https://endpts.com/planning-ahead-for-crowded-ulcerative-colitis-market-pfizer-spells-out-phiii-data-on-6-7b-arena-drug/
https://www.prnewswire.com/news-releases/everest-medicines-licensing-partner-pfizer-presents-elevate-pivotal-findings-demonstrating-etrasimods-potentially-best-in-class-profile-in-ulcerative-colitis-301553701.html
https://www.expresspharma.in/pfizers-bowel-disease-drug-succeeds-in-second-late-stage-study/
https://www.biopharmadive.com/news/pfizer-arena-etrasimod-ulcerative-colitis-results/620878/
https://www.reuters.com/markets/deals/pfizer-acquire-arena-pharmaceuticals-67-bln-deal-2021-12-13/
https://endpts.com/arenas-lead-drug-misses-on-phii-in-ad-thwacking-stock-but-company-soldiers-on-into-phase-iii/
https://www.prnewswire.com/news-releases/arena-reports-third-quarter-financial-results-with-strong-cash-position-advancing-etrasimod-into-a-phase-3-registrational-program-in-atopic-dermatitis-301169036.html
https://www.prnewswire.com/news-releases/arena-pharmaceuticals-advancing-etrasimod-into-phase-3-program-in-atopic-dermatitis-ad-reports-compelling-topline-results-from-phase-2b-advise-trial-301169037.html
https://www.prnewswire.com/news-releases/arena-pharmaceuticals-announces-first-subject-dosed-in-elevate-uc-12-global-phase-3-trial-evaluating-etrasimod-in-ulcerative-colitis-301131854.html
https://www.prnewswire.com/news-releases/arena-pharmaceuticals-announces-first-subject-dosed-in-elevate-uc-12-global-phase-3-trial-evaluating-etrasimod-in-ulcerative-colitis-301131854.html
https://www.prnewswire.com/news-releases/arena-completes-full-enrollment-of-etrasimod-phase-2-advise-trial-for-atopic-dermatitis-provides-program-updates-301064926.html
https://www.prnewswire.com/news-releases/arena-pharmaceuticals-presented-new-phase-2-data-for-etrasimod-and-olorinab-at-the-14th-congress-of-european-crohns-and-colitis-organisation-300808996.html
https://www.reuters.com/article/us-arena-pharma-utd-therapeut/united-therapeutics-to-develop-sell-arena-pharmas-hypertension-treatment-idUSKCN1NK1Q2
https://www.prnewswire.com/news-releases/arena-pharmaceuticals-presented-phase-1-clinical-data-for-ralinepag-in-pulmonary-arterial-hypertension-at-the-european-society-of-cardiology-300703538.html
https://www.prnewswire.com/news-releases/arena-pharmaceuticals-announces-proposed-public-offering-of-common-stock-300617070.html
https://seekingalpha.com/article/4130257-arena-pharmaceuticals-inks-china-deal-2-pipeline-candidates?source=partner_newsnow
Market Place
Share 
